Lung Cancer Blood Test: Early Detection Breakthrough
- This article details a groundbreaking new blood test developed by researchers from North Midlands University Hospitals NHS Foundation Trust, Keele University, and Loughborough University, for the early detection...
- * Technology: The test utilizes Fourier transform infrared (FT-IR) spectroscopy to identify circulating cancer cells based on their unique chemical "fingerprint." It essentially shines infrared light on a...
- In essence, this new blood test represents a significant step forward in cancer detection and management, offering a less invasive and more efficient way to monitor and treat...
Summary of the Article: New Blood Test for Early Lung Cancer Detection
This article details a groundbreaking new blood test developed by researchers from North Midlands University Hospitals NHS Foundation Trust, Keele University, and Loughborough University, for the early detection of lung cancer.
key takeaways:
* Technology: The test utilizes Fourier transform infrared (FT-IR) spectroscopy to identify circulating cancer cells based on their unique chemical “fingerprint.” It essentially shines infrared light on a blood sample and analyzes how it’s absorbed.
* Benefits: This method promises earlier diagnosis, real-time monitoring of cancer progression, reduced need for invasive procedures (like biopsies), and the potential for personalized cancer treatment.
* How it Works: The test can detect even a single lung cancer cell in a blood sample by analyzing the unique way cancer cells absorb infrared light. This is a simpler, faster, and potentially more effective method than current tests.
* Circulating Tumor Cells (CTCs): The test focuses on CTCs, which are cells that break off from the tumor and travel thru the bloodstream. These cells provide valuable details about the cancer’s growth and response to treatment.
* Potential Beyond Lung Cancer: Researchers believe this technology could be adapted to detect many other types of cancer.
* Successful Test Case: The technology was successfully tested on a 77-year-old lung cancer patient.
In essence, this new blood test represents a significant step forward in cancer detection and management, offering a less invasive and more efficient way to monitor and treat the disease.